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Whole Organisms or Pure Compounds?
Entourage Effect Versus Drug Speciﬁcity
Sidarta Ribeiro
Abstract As the therapeutic use of sacred plants and fungi becomes increasingly
accepted by Western medicine, a tug of war has been taking place between those
who advocate the traditional consumption of whole organisms and those who defend
exclusively the utilization of puriﬁed compounds. The attempt to reduce organisms
to single active principles is challenged by the sheer complexity of traditional
medicine. Ayahuasca, for example, is a concoction of at least two plant species
containing multiple psychoactive substances with complex interactions. Similarly,
cannabis contains dozens of psychoactive substances whose speciﬁc combinations
in different strains correspond to different types of therapeutic and cognitive effects.
The “entourage effect” refers to the synergistic effects of the multiple compounds
present in whole organisms, which may potentiate clinical efﬁcacy while attenuating
side effects. In opposition to this view, mainstream pharmacology is adamant about
the need to use puriﬁed substances, presumably more speciﬁc and safe. In this
chapter, I will review the evidence on both sides to discuss the scientiﬁc, economic,
and political implications of this controversy. The evidence indicates that it is time to
embrace the therapeutic complexity of psychedelics.
AsWestern medicine discovers the medicinal properties of whole organisms deemed
sacred by traditional cultures, a ﬁerce debate has been set between proponents of the
use of puriﬁed chemicals versus supporters of long-established ritual uses of plants,
fungi, and animals. As a professional neuroscientist with an interest in psychedelic
medicines, it is clear to me that the attempt to reduce organisms to single active
principles is challenged by the sheer complexity of traditional medicine. Ayahuasca,
for example, is a concoction of at least two plant species containing multiple
psychoactive substances with a plethora of interactions (Dos Santos et al., 2012;
Mckenna, Towers, & Abbott, 1984). Similarly, cannabis contains dozens of psy-
choactive substances whose speciﬁc combinations in different strains correspond to
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distinct types of therapeutic and cognitive effects (Mechoulam, Hanus, Pertwee, &
Howlett, 2014). Is there a scientiﬁc basis for believing that single molecules are more
useful for medicinal purposes than mixtures?
Pharmacopeia of a Single Plant: The Case of Cannabis
Much as the hundreds of dog breeds coevolved with humans in a genetic race for the
satisfaction of quite speciﬁc human needs (Kekecs et al., 2016; Parker et al., 2017),
cannabis coevolved with humans so as to satisfy a wide variety of therapeutic,
recreational, and religious needs (Guy, Whittle, & Robson, 2004; Pollan, 2001).
There are over 700 strains of cannabis (Gloss, 2015; Sawler et al., 2015), each with
characteristic concentrations of hundreds of substances of therapeutic interest, such
as cannabinoids, terpenes, and phenols (Andre, Hausman, & Guerriero, 2016;
Formukong, Evans, & Evans, 1988; Gertsch, Pertwee, & Di Marzo, 2010). Dozens
of cannabinoids have medicinal properties (Izzo, Borrelli, Capasso, Di Marzo, &
Mechoulam, 2009; Radwan et al., 2008). Tetrahydrocannabinol (THC), until
recently the most studied cannabinoid of cannabis, possesses enormous therapeutic
potential, with preliminary or advanced empirical evidence regarding a wide range
of diseases, such as multiple sclerosis (Rekand, 2014; Zettl, Rommer, Hipp, &
Patejdl, 2016), ischemia (Zani, Braida, Capurro, & Sala, 2007), Alzheimer’s disease
(Aso, Sanchez-Pla, Vegas-Lozano, Maldonado, & Ferrer, 2015; Cao et al., 2014; Yu
et al., 2016), lateral amyotrophic sclerosis (Weber, Goldman, & Truniger, 2010),
anorexia (Lewis & Brett, 2010; Verty et al., 2011), Parkinson’s disease (van Vliet,
Vanwersch, Jongsma, Olivier, & Philippens, 2008), diabetes (Gallant, Odei-Addo,
Frost, & Levendal, 2009), cystic ﬁbrosis (Bregman & Fride, 2011), chronic and
neuropathic pain (Cannabis-based Medicines, 2003; Johnson et al., 2010; Johnson,
Lossignol, Burnell-Nugent, & Fallon, 2013), and epilepsy (Maccarrone, Maldonado,
Casas, Henze, & Centonze, 2017). Another very promising recent advance occurred
in cancer; we now know that cannabinoids are useful in onco-therapy, not only to
alleviate anxiety, pain, lack of appetite, and sleep due to chemotherapy or radiother-
apy (Abrams, 2016) but also for their potent antitumor properties (Guzman, 2003;
Huff & Chan, 2000; Ladin, Soliman, Grifﬁn, & Van Dross, 2016; Lombard,
Nagarkatti, & Nagarkatti, 2005).
A major recent breakthrough revealed THC as a contender for holding the biggest
promise of cognitive restoration for the aging human population. The study showed
that chronic THC treatment reverses cognitive decline in older mice, restoring
learning ability to the levels of young animals (Bilkei-Gorzo et al., 2017). THC
treatment also restored synaptic plasticity to the levels typical of young animals, with
a concomitant rescue of plasticity-related mRNA and protein levels and increase in
the density of dendritic spines (Bilkei-Gorzo et al., 2017). The study showed further
that adolescent mice are cognitively impaired after the same treatment, due to
excessive plasticity. While it becomes increasingly clear why the early and excessive
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use of cannabis is ill-advised (Farnsworth, 1976; Schmits & Quertemont, 2013),
cannabis strives to supplant the cane as the elder’s best friend.
Part of the resistance to cannabis as medicine relates to its great potential to
replace or substantially change current therapies. Patients with epilepsy, Parkinson’s
disease, neuropathic pains, and several other illnesses treatable by cannabis are often
refractory to medications presently available for medical prescription (Ohtsuka,
Yoshinaga, & Kobayashi, 2000). This problem is clinically addressed by increasing
medication doses, leading to higher risks of side effects, which may include cardiac
or respiratory arrest (Hookana et al., 2016). In contrast, cannabinoid medications are
very safe to use, since there are no cannabinoid receptors in neurovegetative centers
(Hu & Mackie, 2015; Moldrich & Wenger, 2000; Tsou, Brown, Sanudo-Pena,
Mackie, & Walker, 1998).
The main psychological deﬁcit acutely caused by cannabis intake is an impair-
ment of working memory (Fadda, Robinson, Fratta, Pertwee, & Riedel, 2004).
Interestingly, the scientiﬁc basis for the use of cannabis to treat a variety of diseases
related to excess or inadequate neuronal synchronization, such as epilepsy,
Parkinson’s disease, Tourette syndrome, and chronic and neuropathic pain, is
probably related to the same biological property that impairs working memory in a
dose-dependent manner: the capacity of cannabinoids to desynchronize neuronal
activity (Robbe et al., 2006). Working memory impairment is mostly related to THC
and can be avoided by mixing it with other cannabinoids and terpenes (Cannabis-
based medicines, 2003; Johnson et al., 2013; Koehler, 2014; Maccarrone et al.,
2017; Patti, 2016; Rekand, 2014; Sastre-Garriga, Vila, Clissold, &Montalban, 2011;
Zettl et al., 2016), as typically for in natura cannabis (Russo, 2011). The antide-
pressant effects of cannabis (de Mello Schier et al., 2014; Jiang et al., 2005), as well
as its use to mitigate the consequences of stroke (Bravo-Ferrer et al., 2017), are likely
related to its role in the induction of neurogenesis (Avraham et al., 2014; Jin et al.,
2004; Xapelli et al., 2013).
Plants United, Entourage of Molecules
The understanding of the medicinal use of whole organisms is greatly illuminated by
the notion of entourage effect, a term coined by chemists Raphael Mechoulam and
Simon Ben-Shabat to refer to the cooperative effects of the multiple compounds
present in whole organisms that may potentiate clinical efﬁcacy while attenuating
side effects (Ben-Shabat et al., 1998). One clear example of such entourage effect is
the additive effect of cannabidiol (CBD) and THC, two main constituents of
cannabis, in the enhancement of radiotherapy for the treatment of glioma (Scott,
Dalgleish, & Liu, 2014). Cooperative effects also link cannabinoids to the perfumed
organic compounds called terpenes. Chemically similar to cannabinoids and abun-
dant in cannabis, these substances can facilitate the passage of chemicals through the
blood-brain barrier and counterbalance memory deﬁcits induced by THC (Russo,
2011).
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From the psychiatric point of view, CBD and THC have very different and, in
fact, complementary effects (Fadda et al., 2004; Morgan, Freeman, Schafer, &
Curran, 2010; Morgan, Schafer, Freeman, & Curran, 2010), with relaxation and
sedation following CBD intake and excitation following THC intake. CBD is
anxiolytic and antipsychotic, while THC is anxiogenic and pro-psychotic (Fakhoury,
2016; Sherif, Radhakrishnan, D’Souza, & Ranganathan, 2016; Zuardi et al., 2012).
In isolation and at high doses, these substances may have negative health effects,
especially for people in key populations (Di Forti et al., 2009). On the other hand, the
presence of both compounds in cannabis results in a buffered effect that is anything
but unsafe from the patient’s perspective (Silva, Balbino, & Weiber, 2015).
Did Science Finally Catch Up with the Traditional Shamans?
Is cannabis beneﬁcial? Is cannabis dangerous? Should we legalize cannabis? The
absurdity of these questions can be exposed by performing an apt substitution: Are
dogs beneﬁcial? Are dogs dangerous? Should we legalize dogs? We must not forget
that the traditional use of whole organisms such as cannabis coevolved with the plant
itself (McPartland & Guy, 2004; Pollan, 2001). Cannabis was probably used in the
ﬁrst rope, cloth, paper, and medicine. The Ebers Papyrus of Ancient Egypt
(~1550 BC) contains a prescription of cannabis for inﬂammation (Dawson, 1934).
We now know that the plant contains several anti-inﬂammatory substances (de Lago,
Moreno-Martet, Cabranes, Ramos, & Fernandez-Ruiz, 2012; Fabisiak & Fichna,
2017; Liu, Fowler, & Dalgleish, 2010; Molina-Holgado et al., 2003; Nagarkatti,
Pandey, Rieder, Hegde, & Nagarkatti, 2009; Zurier, 2003). The “Siberian Ice Lady,”
a beautifully tattooed mummy from the ﬁfth century BC, discovered in 1993 in the
Russian Altai Mountains near the borders of China, Mongolia, and Kazakhstan, was
found with a pouch of cannabis at the rich burial site. The mummy also had a
primary tumor in her right breast, with signs of metastasis (Letyagin, Savelov, &
Polosmak, 2014). Could the “Siberian Ice Lady” have used cannabis to treat cancer?
In the past 17 years, biomedical research has shown that cannabinoids have
antitumoral effects in breast cancer and a variety of other cancer types, including
glioma, lung, colon, liver, skin, prostate, thyroid, and pancreatic cancer (Ladin et al.,
2016).
The artiﬁcial selection of cannabis, performed widely in central Asia in the past
6000 years both north and south of the Himalayas, led to strains characterized by
cannabinoid mixtures, rather than strains dominated by a single cannabinoid
(Elsohly & Slade, 2005; Fetterman & Turner, 1972). We know now that an extract
of the entire plant, with similar amounts of THC and CBD (“Sativex”), is more
effective in reducing pain and spasms of multiple sclerosis than the pure synthetic
compound, Dronabinol (“Marinol”), analogous to THC (Keating, 2017). If puriﬁed
compounds were indeed always best for therapy, single-compound strains should
have been favored over time. Yet, the opposite happens to be true. Traditional
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shamans use whole plants and have advocated for this sort of medicine as a major root
of their practice (Labate & Cavnar, 2014a). We should listen to our ancestors here.
“Puriﬁed Compounds Only” Is Snake Oil
What is best for medicinal use, whole organisms or isolated active principles?
Mainstream pharmacology is adamant about the need to use puriﬁed substances
for medical treatment, because these are presumably more speciﬁc and safe (Zuardi,
Crippa, & Hallak, 2010). This position is defended ﬁercely in the media and also in
academic publications, as if there was much more clinical knowledge accumulated
about the effects of the puriﬁed compounds than about the effects of whole organ-
isms; however, this is often not the case. The traditional use of whole organisms has
centuries and, in some cases, millennia of cultural experience, while puriﬁed com-
pounds only recently started to be investigated. As a useful analogy, consider that to
say that the use of puriﬁed cannabinoids is medically safer than the use of cannabis
in natura is similar to the fallacy of considering cesarean delivery scientiﬁcally
superior to natural childbirth. Rimonabant, an anti-obesity medicine based on an
antagonist of a cannabinoid receptor, is the most infamous example of the potential
dangers of a single compound; it was removed from the market in 2008 due to the
association with suicide cases (Rimonabant, 2009; Topol et al., 2010). The whole
cannabis plant, however, with various proportions of THC, CBD, and many other
cannabinoids, is clinically safe for people outside key populations and can even be
used in these populations provided that adequate, speciﬁc strains of cannabis are
used. For example, CBD-rich cannabis is safe for psychotic patients and can be used
as psychiatric treatment (Zuardi et al., 2012). In the case of ayahuasca, compound
combination is advantageous not because of safety issues but due to the fact that the
N-N-dimethyltryptamine (DMT) contained in the plant Psychotria viridis is entirely
degraded by the monoamine oxidases (MAO) present in the gastrointestinal tract in
the absence of pharmacological protection (Buckholtz & Boggan, 1977). Indeed, the
DMT contained in ayahuasca would be innocuous if the brew did not include
another plant, the liana Banisteriopsis caapi, which is rich in inhibitors of MAO
and therefore allows the psychedelic experience to occur. These substances by
themselves increase the levels of dopamine and other neurotransmitters (Iurlo
et al., 2001) and induce the formation of new neurons (Dakic et al., 2016). An
argument favoring isolated compounds can perhaps be made for the use of psilocy-
bin rather than whole mushrooms, although there is no symbolic equivalency
between these forms of use; the rich cultural context of mushroom consumption
comprises an important part of the setting that is absent in the case of ingesting a
puriﬁed compound.
One cornerstone of the mesmerizing argument favoring puriﬁed compounds is
the notion that their biological action is equally “pure” and, therefore, “speciﬁc,” two
very loaded words. Much of the credibility that psychiatrists have in the public
debate, whether it is about the pharmacological treatment of mental illness or about
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drug policy, stems from the well-publicized speciﬁcity of the single compounds sold
as psychiatric drugs. It may be surprising to most readers that the opposite happens
to be true: Single molecules often bind to multiple receptors in the brain (Rickli,
Moning, Hoener, & Liechti, 2016; U’Prichard, 1980), at various dose-dependent
afﬁnities (Hamblin, Leff, & Creese, 1984) and with complex long-distance (alloste-
ric) molecular interactions (Price et al., 2005; Solt, Ruesch, Forman, Davies, &
Raines, 2007). The simple is simply not simple.
Time to Debunk the Prohibition Myths
Facing the inquisition, Galileo Galilei was forced, in 1663, to deny the notion that it
is the Earth that moves around the Sun, not the other way around. Galileo is said to
have muttered Eppur si muove (“And yet it moves”) in an act of resistance to
ecclesiastical irrationalism. This dire situation has parallels today in the deadlock
in the public debate regarding the medical use of cannabinoid and serotonergic
psychedelics.
The risks associated with these substances—in particular, cannabis and THC—have
been used as an intellectual “straw man” in the public debate. Many of the substances
sold in pharmacy are acutely dangerous at high doses, which is not the case with
cannabis. To justify the prohibition of cannabis based on the existence of key
populations at risk for cannabis use is to ignore that every substance has risks. To
give a familiar example, it is not because there are people intolerant to lactose that milk
should be banned. The way to deal with lactose intolerance is to inform consumers
properly and to market lactose-free milk.
The prohibition paradigm feeds from a great degree of media-induced moral
panic targeting speciﬁc illicit drugs (Forsyth, 2001), in disagreement with the
scientiﬁc evidence regarding harm potential (Nutt, King, Phillips, & Independent
Scientiﬁc Committee on Drugs, 2010). The fallacious arguments used to bar whole
organisms from the repertoire of ofﬁcial medical treatment often take the form of
inadequate biological analogies, such as: “The puriﬁed compounds of snake venom
are medicinal, but as a whole snake venom kills.” This proposition does not survive
inspection. The ﬁrst drug derived from snake venom was an inhibitor of the
angiotensin-converting enzyme, a toxin found in the venom of the Brazilian pit
viper Bothrops jararaca (Ferreira, 1965; Rocha e Silva, 1963), and basis of synthetic
compounds used worldwide to control high blood pressure, treat chronic heart
failure, and prevent cardiovascular risk (Flather et al., 2000). Later snake-derived
drugs include a modiﬁed version of an antiplatelet toxin produced by the rattlesnake
Sistrurus miliarius barbouri, used broadly to treat heart attacks and prevent blood
clotting (Phillips & Scarborough, 1997). Both kinds of drugs are dangerous at high
doses (Attaya, Kanthi, Aster, & McCrae, 2009; Augenstein, Kulig, & Rumack,
1988; Coons, Barcelona, Freedy, & Hagerty, 2005; Dawson et al., 1990; Parakh,
Naik, Rohatgi, Bhat, & Parakh, 2009; Park, Purnell, & Mirchandani, 1990), so it is
disingenuous to sustain that whole venoms are lethal but puriﬁed compounds are not.
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The real motivation underlying the venom fallacy is the conﬂict of interest of the
medical establishment, in bed with Big Pharma. Where will the proﬁts come from,
when medicine can be grown at home and used in small, infrequent doses? And yet,
how will it be possible to block patients from accessing the life-transforming
psychedelic medicine at very low cost?
The healthcare regulation of traditional medicine based on whole organisms must
consider regional differences and social inequality. Currently, the illicit drug market
is conducted through retail locations in poor neighborhoods and communities.
Regulation in the context of legalization must be oriented to mitigate regional
imbalances, to encourage harm reduction, and to promote the social inclusion of
those who now live from the illicit market but are usually excluded from the debate
on their regulation. Whole organisms offer hope in the treatment of substance abuse
(Winkelman, 2014), as documented preliminarily for the use of cannabis to treat
crack addiction (Labigalini Jr, Rodrigues, & Da Silveira, 1999) and for the use of
ayahuasca to treat alcohol, tobacco, and cocaine abuse (2014; Thomas, Lucas,
Capler, Tupper, & Martin, 2013).
And Yet It Moves: The Psychedelic Renaissance Is On
The year 2017 will be remembered as a landmark of the “psychedelic renaissance”;
the terrible barriers that have been imposed for decades on the research and the
therapeutic use of psychedelic substances—cannabis, ayahuasca, LSD, psilocybin,
MDMA, DMT, and many others—are being lifted. In April, researchers from around
the world gathered in Oakland for 3 days of intense exchange of knowledge at
Psychedelic Science 2017, a meeting promoted by the Multidisciplinary Association
for Psychedelic Studies (MAPS) and the Beckley Foundation. The ﬁrst time I
attended a MAPS congress, it was its 25th anniversary conference, the Cartographie
Psychedelica in 2011. The bulk of the audience seemed composed of characters
from J. R. Tolkien’s The Lord of the Rings. The California hippie-chic mixed with
few but quite serious scientists in an atmosphere of celebration of the interest of
science in psychedelia. The congress attracted about 1100 people, and most of the
interest seemed to fall on pure compounds of medicinal interest, although ayahuasca
had its own track.
The following MAPS congress I attended, Psychedelic Science 2013, had about
2000 people and a noticeable change in composition. Scientists invaded Tolkien’s
arena, merging with the mythological beings of Middle-Earth in equal proportions.
Anthropologist Beatriz Labate organized a crowded track of presentations on aya-
huasca, marking the heightened public interest regarding traditional medicines that
bring with them as complex cultural package, with a use setting of its own (Labate &
Cavnar, 2013, 2014a, 2014b).
Psychedelic Science 2017 grew like a tsunami. There were over 3000 partici-
pants, lots of renowned scientists, multiple events of scientiﬁc and artistic relevance,
international press, and closed hotel rooms for documentary recording. The beings of
Tolkien practically disappeared, although some still were present, undercover in
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plain clothes. The main difference of the 2017 congress compared to previous ones
was the conspicuous arrival of foundations and companies interested in funding
research on the use of psychedelics to treat anxiety, depression, post-traumatic stress
syndrome, and even cancer. Importantly, the ayahuasca session grew into an entire
track (“Plant Medicine”) dedicated to whole organisms in general.
The meeting was remarkable for bringing up and coming mainstream, traditional,
and syncretic contemporary medicine, together with hardcore science performed by
leading researchers in cell and molecular biology, biochemistry, neurophysiology,
psychology, and psychiatry. Thomas Insel, the 14-year director of the National
Institute of Mental Health (NIMH), who resigned in 2015 to join Verily Life
Sciences (Google’s spin-off) and now heads the neuroscience company
“Mindstrong”, publicly acknowledged the immense therapeutic potential of psyche-
delics. Major advances in basic psychedelic research were presented. For instance,
pharmacologist David Nichols, from Chapel Hill University, reported groundbreak-
ing results on lysergic acid diethylamide (LSD), featured on Cell’s cover, demon-
strating that the molecular structure of the serotonin receptor locks LSD in its
binding site (Wacker et al., 2017). In principle, this mechanism explains the delayed,
and yet intense, long-lasting effects of LSD, even at tiny doses. This likely relates to
the trendy habit of microdosing LSD, by which people seek cognitive and emotional
enhancement without unintended side effects. Microdosing (including the use of
whole plants or concoctions with low concentrations of psychedelic compounds)
should be understood vis-à-vis the fact that most drug effects correlate with dose
according to inverted-U curves, and therefore the use of low doses keeps effects on
the rising side of the dose-response curve.
Also remarkable were the experimental results shown by molecular and cell
biologist Stevens Rehen, from the D’Or Institute for Research and Teaching and
Federal University of Rio de Janeiro, who showed that 5-methoxy-N,N-dimethyl-
tryptamine (5-MeO-DMT), a psychedelic substance present in ayahuasca, in the
indigenous snuff Yopo, and in the Sonoran desert toad Bufo alvarius (Barceloux,
2012), can induce neurogenesis (Dakic et al., 2016) and synaptic plasticity (Dakic
et al., 2017).
Major advances in translational psychedelic research were also featured. The
research presented by neuroscientist Draulio de Araujo was one of the biggest
highlights. With his team from the Federal University of Rio Grande do Norte,
Araujo obtained excellent evidence that ayahuasca is quite useful in the effective
care of treatment-resistant major depression in a randomized, placebo-controlled
clinical trial (Palhano-Fontes et al., 2017). In contrast with regular antidepressants
that take weeks to act, ayahuasca quickly attenuates depressive symptoms (Osorio
et al., 2015), with a signiﬁcant effect 40 min after ingestion (Sanches et al., 2016).
Importantly, when compared to placebo, this effect persists for at least 7 days
(Palhano-Fontes et al., 2017), substantially more than the effect obtained with the
single-molecule ketamine, at present ayahuasca’s direct clinical competitor for fast
yet durable antidepressant effect (Romeo, Choucha, Fossati, & Rotge, 2015; Zarate
Jr et al., 2006). Preliminary results from the Araujo group indicate that the antide-
pressant effect is proportional to the degree of perceptual alteration (Palhano-Fontes,
2017), which is known to involve major activation of visual cortical areas (de Araujo
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et al., 2012). In the author’s own words, “the more intense the psychedelic experi-
ence, the stronger is the antidepressant effect” (Palhano-Fontes, 2017).
Prohibition: What Is to Be Done?
The core issue at stake is the fact that the phyto-therapeutic approach to psychedelic
medicine is successful in multiple countries, and quite scalable, due to the low cost
of home-growing whole organisms. The therapeutic use of cannabis is currently
legal in Austria, Belgium, Canada, Chile, Colombia, the Czech Republic, Finland,
Israel, the Netherlands, Spain, the United Kingdom, Uruguay and several US states.
Ayahuasca is currently legal in multiple countries (Labate & Cavnar, 2014a, 2014b).
Phyto-therapeutic medicine is feasible because doses can be kept within con-
trolled ranges and because knowing the precise dose is often not essential for
effective therapeutics. After all, few would defend the notion that taking vitamin
pills provides better nutrition than eating fresh fruit and vegetables. Puriﬁed com-
pounds are much more expensive to make and necessarily reach the ﬁnal consumer
at much higher prices than whole organisms. The clinical use of puriﬁed compounds
for subjects with low socioeconomic status is further hampered by Big Pharma
patent rights and marketing strategies. Still, in recent years, the large margin of
proﬁt for the commercialization of puriﬁed compounds has motivated a strong
corporative push for the adoption of puriﬁed compounds as the gold standard for
medical practice involving psychedelic substances. In the case of medical marijuana,
cannabis in natura versus isolated cannabinoids is a billion-dollar question.
To make safe use of any substance, it is necessary to understand its use in three
different dimensions of the experience: substance (dose, interaction), set (body and
mind), and setting (social context). Prohibition compromises the three dimensions
altogether. With regard to the substance, it increases the chances of dose uncertainty,
contamination, and degradation. With respect to the set, it hinders free dialogue
about key populations. With regard to the setting, it promotes violence, paranoia,
marginalization, and stigmatization. Prohibition is the heaviest of all drugs, and the
ban on psychedelic drugs leads to unregulated iatrogenic use without harm reduc-
tion, nor scientiﬁc control, decreasing the protection of the society.
In view of current scientiﬁc knowledge (Abrams, 2016; Ben Amar, 2006; Fasinu,
Phillips, ElSohly, &Walker, 2016; Ladin et al., 2016; Rosenberg, Tsien, Whalley, &
Devinsky, 2015; Sznitman & Lewis, 2015), it is of paramount importance for
medicine and research to legalize the use, possession, planting, cultivation,
harvesting, manipulation, manufacture, distribution, marketing, import, export, and
prescription of Cannabis sativa L. and other varieties of cannabis, as well as
products obtained from these plants. The same applies to ayahuasca, peyote, mush-
rooms, toads, and various other psychedelic organisms (Labate & Cavnar, 2014a,
2014b). Whole organisms must be legalized and regulated to protect people at risk
and respect users. These measures will give doctors, patients, and researchers
maximum therapeutic options and the widest range of tools while at the same time
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reducing costs, offering access options according to each patient proﬁle or type of
research, avoiding dependence on foreign products, and preventing patients from
buying medicine from the illicit market of questionable quality and with active
principles in unknown concentrations. These measures will also promote production
by patient associations and promote the self-care of patients who carry out their own
cultivation.
We are living in the era of psychedelic renaissance. Science ﬁnally caught up with
the knowledge, wisdom, and curiosity of healers and psychonauts, and the new
medicine of the future may come from ancient medicine invented by Amazonian
pajés and Siberian shamans of the past. New questions are becoming as widespread
as new answers. Now is the prime time to discuss the potential advantages and
disadvantages of therapeutics based on whole organisms versus puriﬁed compounds,
a debate with major economic, social, and philosophical implications for the future
of human health.
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